![]() |
|
|
Vol. 286, Issue 2, 863-869, August 1998
Department of Pharmacology, School of Medicine, Tokai University, Isehara 259-11, Japan
| |
Abstract |
|---|
|
|
|---|
The amounts of dynorphin-(1-8) [dyn-(1-8)] and its seven hydrolysis products, Y, YG, YGG, YGGF, YGGFL, YGGFLR and YGGFLRR, were estimated after incubating dyn-(1-8) with a membrane fraction from either guinea-pig ileum or striatum for various times at 37°C. The major hydrolysis products during the initial 5-min incubation were YGGFLR and Y, which indicates that dipeptidyl carboxypeptidase and aminopeptidase activities were mainly involved in the hydrolysis. After 60 min of incubation, dyn-(1-8) was completely hydrolyzed in both membrane preparations. When the ileal and the striatal preparations were incubated for 60 min in the presence of both captopril, a dipeptidyl carboxypeptidase inhibitor, and amastatin, an aminopeptidase inhibitor, 63.8 and 49.3% of dyn-(1-8), respectively, were hydrolyzed. The YGG fragment was the major hydrolysis product in both preparations. When the ileal and the striatal membrane fractions were incubated with dyn-(1-8) in the presence of three peptidase inhibitors, captopril, amastatin and phosphoramidon (an inhibitor of endopeptidase-24.11), approximately 95% of the opioid octapeptide remained intact in both cases. This shows that dyn-(1-8) was almost exclusively hydrolyzed by three enzymes, amastatin-sensitive aminopeptidase, captopril-sensitive dipeptidyl carboxypeptidase I and phosphoramidon-sensitive endopeptidase-24.11, in both ileal and striatal membranes. Additionally, the Ke (equilibrium dissociation constant) values of selective antagonists against dyn-(1-8) and its initial main hydrolysis product YGGFLR in two isolated preparations pretreated with the three peptidase inhibitors indicate that the latter acts on mu receptors in guinea pig ileum but delta receptors in mouse vas deferens and the former acts on kappa receptors in both preparations. It is indicated, therefore, that in the absence of peptidase inhibitors endogenously released dyn-(1-8) acts either through dyn-(1-8) itself on kappa receptors or through YGGFLR on mu or delta receptors depending on both the three peptidase activities and the three receptor type densities at the target synaptic membrane.
| |
Introduction |
|---|
|
|
|---|
Three
distinct enzymes, AsA, PsE and CsD, have been shown to play important
roles in the inactivation of exogenously added opioid peptides in
isolated preparations: [Met5]-enkephalin (met-enk) in
guinea pig ileum (Aoki et al., 1984
), mouse vas deferens
(Aoki et al., 1986
) and rat vas deferens (Cui et
al., 1986
); dynorphin-(1-8) [dyn-(1-8)] in guinea pig ileum, mouse vas deferens and rabbit vas deferens (Numata et al.,
1988
) and met-enk-Arg6-Gly7-Leu8
(met-enk-RGL) in guinea pig ileum (Hiranuma et al., 1997
).
The close proximities of these enzymes to the opioid receptors in guinea pig ileum (Aoki et al., 1984
) and mouse vas deferens
(Aoki et al., 1986
) suggest that they function in
terminating the physiological action of endogenous opioid peptides as
well. Additionally, when ileal and striatal membrane fractions are
incubated with met-enk (Hiranuma and Oka, 1986
) or met-enk-RGL
(Hiranuma et al., 1997
) for 60 min at 37°C in the presence
of three PIs (amastatin, captopril and phosphoramidon), approximately
95% of both peptides remain intact. This shows that both met-enk and
met-enk-RGL are almost exclusively hydrolyzed by the three enzymes,
AsA, PsE and CsD, at least in these membrane preparations.
The enzymes involved in the hydrolysis of endogenous opioid peptides
other than the two peptides met-enk and met-enk-RGL, however, have not
been throughly investigated. In the case of dyn-(1-8), an endogenous
opioid peptide that is derived from proenkephalin B (Kakidani et
al., 1982
) and acts on kappa receptors (Corbett et al., 1982
; Oka and Negishi, 1982
), its potency in guinea
pig ileum, mouse vas deferens and rabbit vas deferens has been shown to
be significantly increased by pretreatment of the preparations with the
combination of either four PIs (Corbett et al., 1982
; McKnight et al., 1983
) or three PIs (Numata et
al., 1988
). These results suggest the involvement of several
peptidases in its inactivation. However, it was still unclear how to
prevent completely the hydrolysis of dyn-(1-8). This made it
impossible to determine the potency of dyn-(1-8) accurately, inasmuch
as the determinations were made on partially degraded peptide.
Therefore, we explored methods to protect dyn-(1-8) completely from
degradative hydrolysis. Upon establishing a method that affords the
peptide complete protection, we extended our study to determine the
potency of dyn-(1-8) accurately and compared it with the potencies of
representative opioid agonists.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
Ketocyclazocine was a gift from Sterling-Winthrop
Research Institute (Rensselaer, NY). Captopril was kindly provided by
Sankyo Company (Tokyo, Japan). Other reagents were purchased from the following sources: dyn-(1-8), DAMGO, DPDPE and CTOP (Peninsula Laboratories, Inc., Belmont, CA); Y (tyrosine) [The standard
one-letter, instead of three-letter, codes for amino acids were used
for the hydrolysis products of dyn-(1-8)], YGGFL
([Leu5]enkephalin), dynorphin-(1-17)
[dyn-(1-17)], amastatin and phosphoramidon (Peptide Institute, Inc.,
Minoh, Japan); YG, YGG, YGGF, YGGFLR and YGGFLRR (BACHEM
Feinchemikalien AG, Bubendorf, Switzerland); morphine HCl (Sankyo
Company) and nor-BNI and N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH (Aib =
-aminoisobutyric acid) (ICI-174864) (Research
Biochemicals, Inc., Natick, MA). All chemicals, except for
ketocyclazocine, were dissolved in glassdistilled water.
Ketocyclazocine was dissolved in 0.5 N lactic acid at a concentration
of 30 mM and then diluted with water. The stock solution for all
peptides used was prepared at concentrations of 0.1 to 10 mM in
siliconizing plastic tubes, maintained at
18°C and then diluted to
the desired concentration just before use.
Preparation of membrane fractions.
Male Hartley guinea pigs
weighing 400 to 600 g were used for this study. The myenteric
plexus-longitudinal muscle strip was prepared as previously described
(Oka et al., 1982
). The striatum of the guinea pig brain was
dissected by the method of Glowinski and Iversen (1966)
. Membrane
fractions of the strips or striata were prepared as previously
described (Hiranuma and Oka, 1986
; Hiranuma et al., 1997
).
They were suspended and adjusted with 50 mM Tris-HCl buffer, pH 7.4, to
a concentration of 2 mg/ml of protein, yielding the sample used in the
after experiment as the membrane fraction. Protein concentrations were
measured by the method of Lowry et al. (1951)
, with bovine
serum albumin as the standard.
Hydrolysis of dyn-(1-8). The sample of either the ileal or striatal membrane fraction (0.5 mg of protein) in 50 mM Tris-HCl buffer, pH 7.4, was incubated with dyn-(1-8) (5 nmol) in either the absence or the presence of the PIs for various times at 37°C in a total volume of 0.5 ml. The reaction was stopped by the addition of 0.5 ml of 10% trichloroacetic acid, followed by centrifugation at 3000 rpm for 15 min. A sample (10-20 µl) of the supernatant was then analyzed by HPLC-ECD to assess the product formation.
Separation and detection of dyn-(1-8) and its hydrolysis products by HPLC-ECD. The apparatus consisted of a PM-60 pump (Bioanalytical Systems, Inc., West Lafayette, IN), a µBondasphere 5-µm C18-100Å column (3.9 × 150 mm) (Waters/Nihon Millipore, Ltd., Tokyo, Japan) and an LC-4B electrochemical analyzer (Bioanalytical System, Inc.). The chromatographic mobile phase was 0.1 M phosphate buffer at pH 3.0 containing 2.5% acetonitrile for the Y, YG and YGG assays (fig. 1A); 12% acetonitrile for the YGGF, YGGFL, YGGFLR and YGGFLRR (fig. 1B); and 17% acetonitrole for the dyn-(1-8) (fig. 1C), at the flow rate of 0.8 ml/min. The ECD worked at an applied voltage of 1 V vs. the Ag/AgCl reference electrode. Under these conditions, Y, YG, YGG, YGGF, YGGFL, YGGFLR, YGGFLRR and dyn-(1-8) exhibited a retention time of approximately 3.58, 5.38, 4.77, 4.23, 19.6, 7.10, 4.71 and 4.88 min, respectively (fig. 1A, B and C), and the detection limit of each compound was approximately 2 pmol. The recovery of dyn-(1-8) and those of its hydrolysis products added to the heat-treated membrane fraction (100°C for 5 min) was each more than 95%. Therefore, the amount of each compound was estimated without correcting for its % recovery.
|
Calculations.
The amount of each compound was determined by
comparing the peak heights in the sample with that of the standard.
Working standards were run at regular intervals to check the
sensitivity of the detector. Y was always detected even when the
membrane fraction sample was incubated in the absence of dyn-(1-8) for 60 min (Hiranuma and Oka, 1986
; Hiranuma et al., 1998
).
Therefore, the amount of Y in the absence of dyn-(1-8) was always
subtracted from that in the presence of dyn-(1-8). In contrast to Y,
dyn-(1-8) and its hydrolysis products other than Y were undetectable
in any of the samples incubated in the absence of dyn-(1-8).
In vitro isolated preparation.
Male ICR-Jcl
mice weighing 40 to 50 g and male Hartley guinea pigs weighing 400 to 600 g were used for this study. The mouse vas deferens and the
myenteric plexus-longitudinal muscle strip of guinea pig ileum were set
up for electrical stimulation as described previously (Oka et
al., 1982
). The % inhibition of the stimulated muscle twitch
produced by an opioid was plotted against the log concentration of the
opioid to estimate the IC50 (opioid concentration producing
50% inhibition of the twitch). When the effect of PIs on the
IC50 value of an opioid peptide was studied, they were
given 10 min before the administration of the opioid peptide. The
Ke (equilibrium dissociation constant) values of opioid antagonists against the agonists were determined by the "single dose" method of Kosterlitz and Watt (1968)
. Because the IC50 value of an opioid in one preparation was sometimes
significantly different from those in the others, the same preparation
was used to carry out the experiment on the relative potency of
opioids.
| |
Results |
|---|
|
|
|---|
The time course of the dyn-(1-8) hydrolysis and the generation of hydrolysis products during the incubation with membrane fractions. Dyn-(1-8) (5 nmol) was incubated at 37°C in 50 mM Tris-HCl buffer (pH 7.4) with a membrane fraction (0.5 mg of protein) prepared from either the myenteric plexus-longitudinal muscle strip of guinea pig ileum or the striatum of guinea pig brain. The amounts of dyn-(1-8) and its seven hydrolysis products: Y, YG, YGG, YGGF, YGGFL, YGGFLR and YGGFLRR in the reaction mixture were estimated at 0, 5, 15, 30, 45 and 60 min after starting the incubation. During the initial 5 min of incubation, dyn-(1-8) was hydrolyzed by approximately 44.4 and 41.4% in the ileal (fig. 2A) and striatal (fig. 2B) membrane fraction, respectively, and hydrolyzed almost completely at 60 min after starting the incubation in both membrane preparations (fig. 2A and B). The major hydrolysis products during the initial 5-min incubation were YGGFLR and Y in both preparations (fig. 2A and B), indicating that the dipeptidyl carboxypeptidase and aminopeptidase activities are mainly involved in the dyn-(1-8) hydrolysis.
|
Effects of the PIs on the dyn-(1-8) hydrolysis by the ileal membrane fraction. When the dyn-(1-8) (5 nmol) was incubated with the ileal membrane in the absence of PI for 60 min at 37°C, Y, YG, YGG and YGGF were detected in the sample, whereas YGGFL, YGGFLR, YGGFLRR and dyn-(1-8) were not (table 1). The percent production of Y, YG, YGG and YGGF was 69.4, 12.3, 13.8 and 2.5%, respectively (table 1). In contrast to the results without PI, the presence of 1 µM amastatin decreased the percent production of free Y to 1.0%; increased the percent productions of the YG, YGG and YGGF fragments to 44.9, 44.7 and 5.6%, respectively; and left 1.8% of the dyn-(1-8) intact (table 1). The presence of 1 µM captopril decreased the percent formation of both the YG and the YGGF fragments to 1.6 and 0.2%, respectively; increased both free Y and the YGG fragment to 73.9 and 16.5%, respectively; and left 6.1% of the dyn-(1-8) intact (table 1). In the presence of 1 µM phosphoramidon, the percent generation of the YGG fragment was decreased to 0.3%; percent generations of free Y, the YG and the YGGF fragments were increased to 74.7, 18.9 and 3.5%, respectively; and 0.4% of dyn-(1-8) remained intact (table 1). In the presence of both amastatin and captopril, the main hydrolysis product was the YGG fragment, and 36.2% of the dyn-(1-8) remained intact (table 1). In the presence of both amastatin and phosphoramidon, the main hydrolysis product was the YG fragment, and 38.2% of the dyn-(1-8) remained intact (table 1). When amastatin, captopril and phosphoramidon were all present, 95.0% of the dyn-(1-8) remained intact (table 1).
|
Effects of the PIs on the hydrolysis of dyn-(1-8) by the striatal membrane fraction. The hydrolysis products of dyn-(1-8) formed during a 60-min incubation with the striatal membrane fraction were qualitatively similar to, but quantitatively different from, those yielded by the ileal membrane fraction in either the absence or the presence of the PIs (tables 1 and 2). The free Y generation in the absence of the PIs and the presence of either captopril or phosphoramidon after incubation with the striatal membrane fraction was lower than that observed with the ileal membrane fraction (tables 1 and 2). The formation of the YGG fragment in the absence of the PIs and the presence of amastatin after incubation of dyn-(1-8) with the striatal membrane fraction was lower than that with the ileal membrane fraction (tables 1 and 2). In contrast to the free Y and YGG fragment, the productions of both the YG and YGGF fragments in the absence of the PIs and the presence of phosphoramidon after incubation of dyn-(1-8) with the striatal membrane fraction were higher than that with the ileal membrane fraction (tables 1 and 2). However, the amount of dyn-(1-8) remaining intact 60 min after incubation with the striatal membrane fraction was higher than that with the ileal membrane fraction in the presence of either captopril alone or both amastatin and captopril (tables 1 and 2). In the presence of amastatin, captopril and phosphoramidon, however, 95% of the dyn-(1-8) remained intact after a 60-min incubation with either the ileal or the striatal membrane fraction (tables 1 and 2).
|
Ke values of kappa and
mu antagonists against dyn-(1-8) in guinea pig ileum in
either the absence or the presence of the three PIs.
The
Ke values of nor-BNI, a selective
kappa opioid receptor antagonist (Portoghese et
al., 1988
), and CTOP, a selective mu antagonist (Gulya
et al., 1986
; Pelton et al., 1986
), against morphine, a representative mu agonist, in guinea pig ileum
were 24.8 and 18.2 nM, respectively, although those against
ketocyclazocine, a representative kappa agonist, were 0.491 and 1,760 nM, respectively (table 3). The
Ke values of nor-BNI and CTOP against dyn-(1-8) in guinea pig ileum in the absence of the PIs were 0.715 and 1,060 nM,
respectively, while those in the presence of the three PIs were 0.226 and 824 nM, respectively (table 3). This indicates that dyn-(1-8) acts
on kappa receptors in guinea pig ileum in both the absence
and the presence of the three PIs. In contrast to dyn-(1-8), the
Ke values of nor-BNI and CTOP against YGGFLR, a
major hydrolysis product during the initial 5-min incubation (fig. 2A),
in guinea pig ileum in the presence of the three PIs were 33.6 and 27.7 nM, respectively (table 3), indicating that YGGFLR acts on
mu receptors in guinea pig ileum.
|
Potencies of dyn-(1-8) and its hydrolysis products in guinea pig
ileum.
We examined the potencies of ketocyclazocine and
dyn-(1-17) relative to that of dyn-(1-8) and examined the potencies
of the YGGFLR and YGGF fragments, the two hydrolysis products of
dyn-(1-8), and morphine relative to that of DAMGO, a selective
mu agonist (Handa et al., 1981
; Kosterlitz and
Paterson, 1981
) in guinea pig ileum pretreated with three PIs
(amastatin, captopril and phosphoramidon) at the final concentration of
1 µM each. Pretreatment of the preparation with the three PIs did not
change the respective IC50 value of ketocyclazocine,
dyn-(1-17), morphine and DAMGO, but significantly decreased the
respective IC50 value of dyn-(1-8), YGGFLR and YGGF in
guinea pig ileum (data are not shown). In the presence of the three
PIs, the potencies of dyn-(1-17) and ketocyclazocine were 271 and
78.2% that of dyn-(1-8), respectively (table
4), and the potencies of YGGFLR, YGGF
which had been shown to act on mu receptors (Hiranuma
et al., 1997
), and morphine were 27.3, 0.686 and 8.39% that
of DAMGO, respectively (table 4).
|
Effects of PIs on the Ke values of
kappa and delta antagonists against dyn-(1-8)
in mouse vas deferens.
The Ke values of
nor-BNI and ICI-174864, a selective delta opioid receptor
antagonist (Cotton et al., 1984
), against dyn-(1-8) in
mouse vas deferens were, respectively, 2.08 and 35.9 nM in the absence
of any of the PIs; 0.0906 and 18,800 nM in the presence of captopril;
1.92 and 23.2 nM in the presence of both amastatin and phosphoramidon;
and 0.0556 and 13,500 nM in the presence of the three PIs (table
5). Additionally, the
Ke values of nor-BNI and ICI-174864 against the
YGGFLR fragment in mouse vas deferens were 3.85 and 11.4 nM,
respectively, in the presence of the three PIs, indicating that the
YGGFLR fragment acts on delta receptors in mouse vas
deferens. The results indicate that in mouse vas deferens, dyn-(1-8)
acts on kappa receptors in the presence of captopril, but in
the absence of captopril, a large part of the dyn-(1-8) is hydrolyzed
to the YGGFLR fragment, which then acts on delta receptors.
|
| |
Discussion |
|---|
|
|
|---|
The hydrolysis of dyn-(1-8) has been examined by incubating it with the membrane fraction prepared from either the myenteric plexus-longitudinal muscle strip of guinea pig ileum or guinea pig striatum in either the absence or presence of the PIs. Our results show that dyn-(1-8) is completely hydrolyzed during the 60-min incubation in the absence of the three PIs, but in their presence, its hydrolysis is almost completely prevented. Until now, the potency of dyn-(1-8) has not been accurately estimated due to its susceptibility to degradation. In our study, by using the three PIs to eliminate hydrolytic inactivation of dyn-(1-8), we were able to determine its potency and compare it to those of representative opioids.
The fact that the major hydrolysis product of dyn-(1-8) is the YGGFLR fragment during the first 5 min of incubation in both the ileal and striatal membrane fractions indicates that the dipeptidyl carboxypeptidase activity is mainly involved in the hydrolysis of dyn-(1-8). Additionally, the observation that the amount of the YGGFLR fragment decreases while that of the YGGF fragment concomitantly increases from 5 to 15 min after initiation of the incubation indicates that the YGGFLR and the YGGF fragments are sequentially produced in this order by the dipeptidyl carboxypeptidase.
The dipeptidyl carboxypeptidase activity in both membrane fractions can
be identified as CsD by the fact that YGGF fragment generation during
the 60-min incubation was almost completely prevented by the presence
of captopril, a specific inhibitor of dipeptidyl carboxypeptidase I
(Rubin et al., 1978
). Similarly, the enzyme activity
producing the free Y and the YGG fragment can be identified as AsA and
PsE, respectively, because the productions of the free Y and YGG
fragment were almost completely prevented by amastatin, a potent
inhibitor of aminopeptidase (Matsas et al., 1985
), and
phosphoramidon, a specific inhibitor of endopeptidase-24.11 (Matsas
et al., 1983
), respectively.
When dyn-(1-8) is incubated with the ileal or striatal membrane fraction for 60 min in the presence of captopril, 74 or 54%, respectively, of dyn-(1-8) is hydrolyzed to the free Y. This indicates that when CsD is inhibited, dyn-(1-8) is hydrolyzed mainly by AsA. Additionally, when dyn-(1-8) is incubated with the ileal or striatal membrane fraction for 60 min in the presence of both captopril and amastatin, 56 or 44%, respectively, of dyn-(1-8) is hydrolyzed to the YGG fragment. This indicates that when both CsD and AsA are inhibited, PsE is then able to hydrolyze a significant amount of dyn-(1-8). The involvement of PsE in the hydrolysis of dyn-(1-8) is also supported by the observation that when enkephalin octapeptide is incubated with the ileal or striatal membrane fraction for 60 min in the presence of the three PIs, amastatin, captopril and phosphoramidon, approximately 95 or 95%, respectively, of the dyn-(1-8) remains intact.
Because the hydrolysis products of dyn-(1-8) by either AsA or PsE such
as free Y and the YGG, [des-Y]-dyn-(1-8) and [des-YGG]-dyn-(1-8) fragments are suggested to have very low, if any, agonist activity against opioid receptors (Morley, 1980
), the potency of dyn-(1-8) is
expected to be decreased by its hydrolysis by these two peptidases. In
fact, the potency of dyn-(1-8) in guinea pig ileum has been shown to
be significantly increased by either amastatin or phosphoramidon in the
previous investigation (Numata et al., 1988
). Additionally, the pharmacological evidence obtained in the previous study (Numata et al., 1988
) showing that the magnitude of the enhancement
of the dyn-(1-8) potency by amastatin is significantly higher than that by phosphoramidon is consistent with the present biochemical data
indicating that AsA is involved in the dyn-(1-8) hydrolysis to a
significantly higher degree than PsE.
In contrast to the hydrolysis products of dyn-(1-8) by AsA and PsE, the YGGFLR fragment, the initial hydrolysis product of dyn-(1-8) by CsD, still has the high agonist activity on opioid receptors. The Ke values of highly selective mu, kappa and delta antagonists against YGGFLR indicate that YGGFLR acts on mu receptors in guinea pig ileum and delta receptors in mouse vas deferens. The Ke values of ICI-174864 and nor-BNI against dyn-(1-8) indicate that dyn-(1-8) acts on delta receptors in mouse vas deferens in the absence of captopril although it acts on kappa receptors in the presence of captopril. These results suggest that in mouse vas deferens, a large part of exogenously added dyn-(1-8) must be hydrolyzed to the YGGFLR fragment, which then interacts with delta receptors, in the absence of captopril. In contrast to mouse vas deferens, the Ke value of nor-BNI against dyn-(1-8) indicates that dyn-(1-8) acts on kappa receptors in guinea pig ileum in both the presence and the absence of captopril. This indicates that in guinea pig ileum, the ratio of dyn-(1-8), which acts on kappa receptors, to YGGFLR, which acts on mu receptors, is high at the vicinity of opioid receptors due to the low activity of CsD. The present results obtained by employing the two isolated preparations strongly suggest that endogenous dyn-(1-8) released from the nerve cell acts through dyn-(1-8) itself or its main hydrolysis product, YGGFLR, on either kappa, mu or delta opioid receptors, depending on both the relative activity of the three enzymes, AsA, CsD and PsE, at the vicinity of opioid receptors and the relative density of the three opioid-receptor types, kappa, mu and delta receptors, at the synaptic membrane.
The electrically evoked contractions of guinea pig ileum were shown to
be inhibited by mu and kappa agonists but not by
delta agonists (Lord et al., 1977
). In our study,
we showed that dyn-(1-8) acts on the kappa receptors, being
consistent with the previous findings (Corbett et al., 1982
;
Oka and Negishi, 1982
), although its hydrolysis products, the YGGFLR
and YGGF fragments, act on the mu receptors in guinea pig
ileum pretreated with the three PIs. Because the potency of dyn-(1-8)
has yet to be estimated under conditions where its degradation is
completely prevented, we determined its potency and compared it with
those of representative kappa agonists in guinea pig ileum
pretreated with three PIs, a condition that totally prevents
hydrolysis. The present results show that the rank order of potencies
is as follows: dyn-(1-17) > dyn-(1-8) > ketocyclazocine.
Additionally, we determined the potencies of the hydrolysis products of
dyn-(1-8) and compared them with those of representative mu
agonists in guinea pig ileum pretreated with the three PIs. Our results
taken together with previous ones (Hiranuma et al., 1997
)
show that the rank order of potencies is as follows: YGGFMR > DAMGO > met-enk-RGL > YGGFLR > morphine
YGGF.
Moreover, our preliminary experiments showed that the potency of YGGFLR
was 45% that of [D-Pen2,5]-enkephalin, a
representative potent delta agonist (Mosberg et al., 1983
), in mouse vas deferens in which YGGFLR was shown to act
on delta receptors, in our study. These results show that the YGGFLR fragment, the initial hydrolysis product of dyn-(1-8), still has the ability to act as a potent agonist on either
mu or delta opioid receptors.
The data obtained in the previous studies in which the effects of three
PIs, amastatin, captopril and phosphoramidon, on the hydrolysis of
met-enk (Hiranuma and Oka, 1986
) and met-enk-RGL (Hiranuma et
al., 1997
) were investigated, together with those obtained in the
present investigation show that three endogenous opioid peptides,
met-enk, met-enk-RGL and dyn-(1-8), are almost exclusively hydrolyzed
by three distinct enzymes, AsA, CsD and PsE, in both ileal and striatal
membrane fractions. Additionally, our recent experiment (Hiranuma
et al., 1998
) showed that the hydrolysis of
[Leu5]-enkephalin and
[Met5]-enkephalin-Arg6-Phe7 in
the membrane fractions is also almost completely prevented by the
mixture of these three PIs. Because all three enzymes have been
indicated to be very closely located to opioid receptors in previous
studies (Aoki et al., 1984
, 1986
; Cui et al.,
1986
; Numata et al., 1988
), they must play critical roles in
the physiological inactivation of several endogenous opioid peptides.
Interestingly, all three enzymes are also indicated to have important
functions in the inactivation of opioid peptides after their systemic
administration by the fact that the s.c. administration of met-enk is
shown to produce two naloxone-reversible effects: inhibition of the
tail-flick response and loss of the righting reflex in 10-day-old rats
pretreated with all three PIs, but not in those pretreated with any
combination of two PIs (Oka et al., 1992
).
| |
Acknowledgments |
|---|
The authors thank Dr. S. M. Jung, Institute of Life Science, Kurume University, Kurume, Japan, for helpful comments and thank Mrs. Kazuko Aoki for her expert technical assistance. The generous gifts of ketocyclazocine and captopril described in "Materials and Methods" are gratefully acknowledged.
| |
Footnotes |
|---|
Accepted for publication April 10, 1998.
Received for publication January 28, 1998.
1 This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.
Send reprint requests to: Dr. Tetsuo Oka, Department of Pharmacology, School of Medicine, Tokai University, Isehara 259-11, Japan.
| |
Abbreviations |
|---|
dyn-(1-8) and -(1-17), dynorphin-(1-8) and
-(1-17);
AsA, amastatin-sensitive aminopeptidase(s);
PsE, phosphoramidon-sensitive endopeptidase-24.11 ("enkephalinase", EC
3.4.24.11);
CsD, captopril-sensitive dipeptidyl carboxypeptidase I
(angiotensin 1 converting enzyme, kininase II, EC 3.4.15.1) ;
met-enk, [Met5]-enkephalin;
met-enk-RGL, [Met5]-enkephalin-Arg6-Gly7-Leu8;
PI, peptidase inhibitor;
DAMGO, [D-Ala2,
N-Me-Phe4,Gly-ol]-enkephalin;
DPDPE, [D-Pen2,5]-enkephalin;
CTOP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2;
nor-BNI, nor-binaltorphimine HCl tetrahydrate;
ICI-174, 864,
N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH (Aib =
-aminoisobutyric acid);
HPLC-ECD, high-performance liquid
chromatography combined with electrochemical detection;
The standard
one-letter, instead of three-letter, codes for amino acids were
employed for the hydrolysis products of dyn-(1-8) .
| |
References |
|---|
|
|
|---|
-subtype of opiate receptor.
Nature
299:
79-81[Medline].
-receptor.
Eur J Pharmacol
97:
331-332[Medline].
-LPH61-64 possessing selective agonist activity at µ-opiate receptors.
Eur J Pharmacol
70:
531-540[Medline].
-neo-endorphin/dynorphin precursor.
Nature
298:
245-249[Medline].
opioid receptors.
Proc Natl Acad Sci USA
80:
5871-5874
-receptors as agonists.
Life Sci
31:
1707-1710[Medline].
-receptors.
Eur J Pharmacol
77:
137-141[Medline].
opioid receptor antagonist selectivity.
J Med Chem
31:
836-841[Medline].This article has been cited by other articles:
![]() |
C. H. Brown and C. W. Bourque Autocrine feedback inhibition of plateau potentials terminates phasic bursts in magnocellular neurosecretory cells of the rat supraoptic nucleus J. Physiol., June 15, 2004; 557(3): 949 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Song and J. C. G. Marvizon Peptidases Prevent {micro}-Opioid Receptor Internalization in Dorsal Horn Neurons by Endogenously Released Opioids J. Neurosci., March 1, 2003; 23(5): 1847 - 1858. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||